Treatment of Haemophilia A Without Inhibitors: Real-World Treatment Patterns and Clinical
Outcomes in the US

Authors: Wheeler, AP; Amos, LE; Gupta, S; Bozzi, S; Miles, G; Hawaldar, K; Wilson, A; Hanson, G; Cibelli, E; Wilson, A; Umarje, S; Tardy, A-L; Dumont, J; Neill, G; Arnaud, A

Affiliations: Washington Center for Bleeding Disorders, Seattle, Washington, USA. Department of Paediatric Haematology-Oncology and Haematology-Oncology, University of Washington, Seattle, Washington, USA. University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA. Division of Haematology/Oncology, Children’s Mercy Kansas City, Kansas City, Missouri, USA. Arnold Palmer Hospital For Children, Orlando, Florida, USA. Sanofi, Gentilly, France. Sanofi, Cambridge, Massachusetts, USA. PicnicHealth, San Francisco, California, USA. Sanofi, Reading, UK.

Publication: Haemophilia;2026

ABSTRACT: INTRODUCTION: Despite available prophylactic therapies for haemophilia A, breakthrough bleeding and consequent pain and joint damage still occur. AIM: To provide insights into the unmet treatment needs of people with moderate-to-severe haemophilia A in the US. METHODS: For this descriptive, observational cohort study, eligible participants diagnosed with moderate-to-severe haemophilia A were enrolled in the PicnicHealth database on or before 3 October 2022. Three patient groups were established to identify: (1) treatment patterns; (2) clinical outcomes by therapy class (standard half-life [SHL] factor VIII [FVIII]; extended half-life FVIII [EHL]; emicizumab); (3) health-related quality of life (HRQoL) using the Patient-Reported Outcomes Measuring Instruments System (PROMIS)-29 survey and a supplemental pain survey. Patients switching treatment classes were included in multiple treatment groups. RESULTS: Of 211 participants in the ‘treatment patterns population’, 123 (58.3%) used SHL FVIII prophylaxis, 81 (38.4%) EHL FVIII prophylaxis, and 83 (39.3%) emicizumab prophylaxis. In the ‘clinical outcomes population’, 63 participants (70.8%) receiving SHL, 43 (61.4%) EHL and 36 (62.1%) emicizumab had ≥1 bleed at Year 1. Pain-related events within the past year occurred in 18 (12.8%), 16 (18.2%) and 10 (12.2%) participants, respectively. The most frequent patient-reported symptoms were ‘sleep disturbance’ (84.5%), ‘inability to participate in social roles and activities’ (69.7%) and ‘fatigue’ (66.9%). The most impacted PROMIS scores were anxiety and pain interference. CONCLUSION: Regardless of the prophylaxis product class used, most participants experienced ≥1 bleeding event per year and reduced QoL. Further treatment optimisation may be needed to prevent bleeding episodes and improve patient QoL.